Drug therapy of heart failure: An immunologic view

American Journal of Therapeutics

Volumn 18, Issue 5, 2011, Pages 416-425

  El Desoky, Ehab S ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

drug therapy; heart failure; inflammatory cytokines

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIGOXIN; ENALAPRIL; EPLERENONE; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 6; LOSARTAN; METHOTREXATE; METOPROLOL; PENTOXIFYLLINE; SPIRONOLACTONE;

ANTIINFLAMMATORY ACTIVITY; AUTONOMIC NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL RESEARCH; CYTOKINE PRODUCTION; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INFLAMMATION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIAC OUTPUT; CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; INFLAMMATION; PROGNOSIS;

EID: 80052735260     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d169db     Document Type: Review

References (106)

1. Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed. Philadelphia: WB Saunders; 2001:503-533.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant. 2002;21:189-203.
3. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90: 464-470. (Pubitemid 38406929)
4. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95:C3-C8.
5. Chen D, Assad Kottner C, Orrego C, et al. Cytokines and acute heart failure. Crit Care Med. 2008;36:S9-S16.
6. Prabhu SD, Chandrasekar B, Murray DR, et al. b-Adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101:2103-2109. (Pubitemid 30233176)
7. Erratum in Circulation. 2000;102:141.
8. Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail. 2001;3:517-267.
9. Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail. 1999;1:309-312. (Pubitemid 30131038)
10. Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: an example of systemic inflammatory disease resulting in cachexia. Int J Cardiol. 2002;85:33-49.
11. Blun A. Immunological mediated therapies for heart failure. IMAJ. 2009;11:301-305.
12. Gong KZ, Song G, Spiers JP, et al. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. Int J Clin Pract. 2007;61:611-621. (Pubitemid 46449822)
13. Torre-Amione G, Anker SD, Bourge RC, et al. Advanced chronic heart failure clinical assessment of immune modulation therapy investigators. Results of a nonspecific immune-modulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomized trial. Lancet. 2008;371:228-236.
14. Francis GS. Pathophysiology of chronic heart failure. Am J Med. 2001;110(Suppl 7A):S37-S46.
15. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol. 2003;41:1606-1610. (Pubitemid 36543382)
16. Hernandez-Presa M, Bustos C, Ortega M, et al. Angiotensin converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-1541. (Pubitemid 27142812)
17. Luft FC. Workshop: mechanisms and cardiovascular damage in hypertension. Hypertension. 2001;37:594-598. (Pubitemid 32199033)
18. Kalra D, Sivasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation. 2002;105:2198-2205. (Pubitemid 34517165)
19. Gullestad L, Aukrust P, Ueland T, et al. Effect of high versus low dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34:2061-2067. (Pubitemid 30002665)
20. Gurlek A, Kilickap M, Dincer I, et al. Effect of losartan on circulating TNF alpha levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk. 2001;8:279-282. (Pubitemid 33010687)
21. Driessler F, Venstrom K, Sabat R, et al. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kB activity: a role for p50. Clin Exp Immunol. 2004; 135:64-73. (Pubitemid 38067929)
22. Waehre T, Halvorsen B, Damas JK, et al. Inflammatory imbalance between IL-10 and TNF-a in unstable angina: potential plaque stabilizing effects of IL-10. Eur J Clin Invest. 2002;32:803-810. (Pubitemid 35356931)
23. Kaur K, Sharma AK, Singal PK. Significance of changes in TNF-a and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:H106-H113.
24. Flesch M, Hoper A, Dell Italia L, et al. Activation and functional significance of the renin angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003;108:598-604. (Pubitemid 36961176)
25. Sekiguchi K, Li X, Coker M, et al. Cross regulation between renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res. 2004;63:433-442. (Pubitemid 38970187)
26. Gurantz D, Cowling RT, Villareal FJ, et al. Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors on cardiac fibroblasts. Circ Res. 1999;85:272-279. (Pubitemid 29377299)
27. Peng J, Gurantz D, Tran V, et al. Tumor necrosis factoralpha induced cardiac fibroblast responses that favor fibrosis. Circ Res. 2002;91:1119-1126.
28. Gurantz D, Cowling RT, Varki N, et al. IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol. 2005;38:505-515. (Pubitemid 40331941)
29. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Consensus trial study group. Circulation. 1990; 82:1730-1736. (Pubitemid 20367976)
30. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 2003;285:H813-H821. (Pubitemid 36885915)
31. Pitt B, Stier CT Jr, Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:164-168. (Pubitemid 37407163)
32. Luft FC. Mechanisms and cardiovascular damage in hypertension. Hypertension. 2001;37:594-598. (Pubitemid 32199033)
33. Francis J, Weiss RM, Johnson AK, et al. Central mineralocorticoid receptor blockade decreases TNFalpha after coronary artery ligation in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R328-R335. (Pubitemid 36120147)
34. Kang YM, Zhang ZH, Johnson RF, et al. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemic-induced heart failure. Circ Res. 2006; 99:758-766. (Pubitemid 44498309)
35. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102(Suppl 4):IV14-IV23.
36. Haskin GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621. (Pubitemid 16081418)
37. Koller-Strametz J, Pacher R, Frey B, et al. Circulating tumor necrosis factor alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant. 1998;17: 356-362. (Pubitemid 28196954)
38. Cicoira M, Bolger AP, Doehner W, et al. High tumor necrosis factor alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001;15:80-86. (Pubitemid 34920508)
39. Leicht M, Briest W, Zimmer HG. Regulation of norepinephrine-induced proliferation in cardiac fibro-blasts by interleukin-6 and p42 mitogen activated protein kinase. Mol Cell Biochem. 2003;243:65-72. (Pubitemid 36240552)
40. Jaffre F, Callebert J, Sarre A, et al. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1b, and tumor necrosis factor-a cytokine production by ventricular fibroblasts. Circulation. 2004; 110:969-974. (Pubitemid 39128622)
41. Du JH, Guan TJ, Zhang H, et al. Phenylarsine oxide inhibited b-adrenergic receptor mediated IL-6 secretion: inhibition of cAMP accumulation and CREB activation in cardiac fibroblasts. Biochem Biophys Res Commun. 2007; 352:744-749. (Pubitemid 44880318)
42. Elenkov IJ, Wilder RI, Chrousos GP, et al. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595-638.
43. Berkenbosch F, de Goeij DE, Rey AD, et al. Neuroendocrine, sympathetic and metabolic responses induced by interleukin-1. Neuroendocrinology. 1989;50:570-576. (Pubitemid 19249102)
44. Mann DL. Inflammatory mediators and the failing heart: past, present and the foreseeable future. Circ Res. 2002;91: 988-998. (Pubitemid 35416635)
45. von Haehling S, Schefold JC, Springer J, et al. The cholesterol paradox revisited: heart failure, systemic inflammation and beyond. Heart Fail Clin. 2008;4:141-151. (Pubitemid 351539135)
46. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic stimulatory response to endotoxin. Nature. 2000;405:458-462. (Pubitemid 30367422)
47. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384-388. (Pubitemid 36157937)
48. Ulloa L. The vagus nerve and the nicotinic antiinflammatory pathway. Nat Rev. 2005;4:673-684. (Pubitemid 41149761)
49. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
50. Fukuzawa M, Satoh J, Sagara M, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor alpha in vitro and in vivo. Immunopharmacology. 1997;36:49-55. (Pubitemid 27153477)
51. Peeters AC, Netea MG, Kullberg BJ, et al. The effect of renin angiotensin system inhibitors on pro-and antiinflammatory cytokine production. Immunology. 1998;94: 376-379. (Pubitemid 28318603)
52. Zhao SP, Xie XM. Captopril inhibits the production of tumor necrosis factor-a by human mononuclear cells in patients with congestive heart failure. Clin Chim Acta. 2001;304:85-90.
53. Andrzejczak D, Gó rska D, Czarnecka E. Influence of enalapril, quinapril and losartan on lipopolysaccharide (LPS)-induced serum concentrations of TNF-alpha, IL-1 beta, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep. 2007;59:437-446. (Pubitemid 47554824)
54. Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin 6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000;35:714-721. (Pubitemid 30167029)
55. Lijnen PJ, Petrov VV, Fagard RH. Collagen production in cardiac fibroblasts during inhibition of angiotensin converting enzyme and aminopeptidases. J Hypertens. 2004;22:209-216. (Pubitemid 38293549)
56. Tsutamoto T, Wada A, Matsumoto T, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing heart of patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37: 2086-2092. (Pubitemid 32548002)
57. Westermann D, Rutschow S, Jäger S, et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism Diabetes. 2007;56:641-646.
58. Benson SC, Iguchi R, Ho CI, et al. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens. 2008;26: 973-980. (Pubitemid 351520985)
59. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial modeling. Pharmacol Ther. 2009;123:255-278.
60. Miura R, Nakamura K, Miura D, et al. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Sci. 2006;102: 288-295. (Pubitemid 44790690)
61. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
62. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett. 2004;91:87-91. (Pubitemid 38296363)
63. Stassen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465. (Pubitemid 12203819)
64. Cohn JN, Anand IS, Latini R, et al. Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108:1306-1309. (Pubitemid 37179882)
65. Folkeringa RJ, Pinto YM, Crijns HJ. Aldosterone levels after angiotensin receptor blocker treatment. Circulation. 2004;109:e182.
66. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002;144:S2-S7. (Pubitemid 35316398)
67. Struthers AD, MacDonald TM. Review of aldosteroneand angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663-670. (Pubitemid 38249465)
68. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13. (Pubitemid 36835815)
69. Gllestad L, Ueland T, Brunsvig A, et al. Effect of metoprolol on cytokine levels in chronic heart failure-a substudy in the metoprolol controlled release randomized intervention trial in heart failure (MERIT-HF). Am Heart J. 2001;141:418-421. (Pubitemid 32200270)
70. Matsumura T, Tsushima K, Ohtaki E, et al. Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J Cardiol. 2002;39:253-257. (Pubitemid 40745785)
71. Mayer B, Holmer SR, Hangstenberg C, et al. Functional improvement in heart failure patients treated with betablockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103:182-186. (Pubitemid 41096032)
72. Li B, Liao YH, Cheng X, et al. Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. Int J Cardiol. 2006;111: 247-255. (Pubitemid 44131484)
73. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function, and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol. 2005;21:344-348. (Pubitemid 40662881)
74. Tatli E, Kurum T, Aktoz M, et al. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure. Int J Cardiol. 2008;125: 273-276. (Pubitemid 351400236)
75. Van Veldhuisen DJ, De Graeff PA, Remme WJ, et al. Value of digoxin in heart failure and sinus rhythm: new features of an old drug? J Am Coll Cardiol. 1996;28: 813-819. (Pubitemid 26348141)
76. Matsumori A, Yamada T, Suzuki H, et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1999;72:561-566.
77. Ihenetu K, Qazzaz HM, Crespo F, et al. Digoxin-like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. Clin Chem. 2007; 53:1315-1322. (Pubitemid 47020988)
78. Matsumori A, Ono K, Nishio R, et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside oubain. Circulation. 1997;96:1501-1506. (Pubitemid 27375343)
79. Ihenetu K, Espinosa R, de Leon R, et al. Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines. Inflamm Res. 2008;57:519-523.
80. Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis. A possible mechanism of digitalis toxicity. Jpn Circ J. 1999;63:934-940. (Pubitemid 30002057)
81. Mahe I, Chassany O, Grenard AS, et al. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction. Am J Cardiovasc Drugs. 2003;3: 33-41. (Pubitemid 36240413)
82. Mohler ER, Sorensen LC, Ghali TK, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol. 1997;30:35-41. (Pubitemid 27357124)
83. Salomon P, Halawa B, Karolko PB. Influence of amlodipine on serum level of some cytokines in patients with congestive heart failure. Pol Arch Med. 2003;109: 149-155. (Pubitemid 36378244)
84. Shima E, Katsube M, Kato T, et al. Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens. 2008;21:78-84.
85. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412-420. (Pubitemid 40216304)
86. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305-311. (Pubitemid 38230289)
87. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic disease. Br J Rheumatol. 1997;36:1196-1204.
88. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology. 2005;44: 677-680. (Pubitemid 41487243)
89. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156: 336-341.
90. Gong K, Zhang Z, Sun X, et al. The nonspecific antiinflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J. 2006;151: 62-68. (Pubitemid 41815332)
91. Fichtlscherer S, Rossig L, Breuer S, et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation. 2001;104:3023-3025. (Pubitemid 34014050)
92. Zhao P, Gong K, Song G, et al. Antiinflammatory effects of methotrexate improves cardiac remodeling and function in a rat model of dilated cardiomyopathy. Acta Pharmacol Sin. 2006;27(Suppl 1):137-138.95.
93. Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. 2006;54:60-67. (Pubitemid 43122187)
94. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-1357.
95. Tsouli SG, Liberopoulos EN, Goudevenos JA, et al. Should a statin be prescribed to every patient with heart failure? Heart Fail Rev. 2008;13:211-225. (Pubitemid 351445343)
96. Tousoulis D, Charakida M, Stefanadi E, et al. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol. 2007;115:144-150. (Pubitemid 46136536)
97. Cheng X, Ding Y, Xia C, et al. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail. 2009;15:158-162.
98. Kotyla PJ. Atorvastatin pleiotropic effects mediated via suppression of TNF-a in congestive heart failure patients with initial normal TNF-a levels. J Heart Lung Transplant. 2009;28:114-115.
99. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12: 464-472. (Pubitemid 46106977)
100. Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1561-1569. (Pubitemid 47532323)
101. Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005; 7:1059-1069. (Pubitemid 41443603)
102. Cleland JG, Loh H, Windram J, et al. Threats, opportunities, and statins in the modern management of heart failure. Eur Heart J. 2006;27:641-643.101.
103. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261. (Pubitemid 350190755)
104. Gissi-HF Investigators: Tavazzi L,Maggioni AP,Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet. 2008;372:1231-1239.
105. Zykov KA, Tatenkulova SN, Mareev VIU, et al. The study of peculiarities of immunotropic action of statins in chronic heart failure of various etiology. Kardiologiia. 2009;49:29-36.
106. Tousoulis D, Papageorgiou N, Briasoulis A, et al. The failure of immunomodulation therapy in heart failure: does the statins paradigm prove the rule? Curr Vasc Pharmacol. 2010;8:114-121.